|

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

RECRUITINGPhase 2Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 2
SponsorEli Lilly and Company
Started2025-08-07
Est. completion2030-05
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07162181

Summary

The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Currently enrolled and active in the originator study, JZNJ. A participant is considered active in the study if they are receiving study intervention
* Agree to comply with contraception requirements. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Exclusion Criteria:

* Are pregnant, or intend to become pregnant during the study, or within 30 days of last dose of study treatment or to breastfeed during the study or within 1 week of the last dose of study treatment

Conditions4

B Cell LymphomaCancerLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-Hodgkin

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.